UniQure sinks as Huntington's gene therapy appears to show waning benefit over time
UniQure's shares {$QURE} were rocked Tuesday morning after the company revealed its experimental Huntington’s disease gene therapy may have less benefit than originally thought. In an additional year of follow-up data, the experimental treatment — known ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
